These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 23123929)

  • 1. New class of kinase inhibitors poised to join the anticancer arsenal.
    Opar A
    Nat Rev Drug Discov; 2012 Nov; 11(11):819-20. PubMed ID: 23123929
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.
    Sullivan RJ; Atkins MB
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1205-16. PubMed ID: 20687784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C; Settleman J
    Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and development of aurora kinase inhibitors as anticancer agents.
    Pollard JR; Mortimore M
    J Med Chem; 2009 May; 52(9):2629-51. PubMed ID: 19320489
    [No Abstract]   [Full Text] [Related]  

  • 8. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
    Friday BB; Adjei AA
    Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p38 MAP kinase: a convergence point in cancer therapy.
    Olson JM; Hallahan AR
    Trends Mol Med; 2004 Mar; 10(3):125-9. PubMed ID: 15102355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRC as a potential therapeutic target in solid tumor oncology.
    Gallick GE
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel targets in solid tumors: MEK inhibitors.
    Messersmith WA; Hidalgo M; Carducci M; Eckhardt SG
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):831-6. PubMed ID: 17143253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic targets.
    Farley J; Birrer MJ
    Cancer Treat Res; 2009; 149():63-84. PubMed ID: 19763431
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting protein kinases in cancer therapy: a success?
    Pearson MA; Fabbro D
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1113-24. PubMed ID: 15606337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Issues and progress with protein kinase inhibitors for cancer treatment.
    Dancey J; Sausville EA
    Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AURKA inhibitors: right in time.
    Kovar H
    Pediatr Blood Cancer; 2010 Jul; 55(1):3-4. PubMed ID: 20486161
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting the ERK signaling pathway in cancer therapy.
    Kohno M; Pouyssegur J
    Ann Med; 2006; 38(3):200-11. PubMed ID: 16720434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase inhibitors: breakthrough medicines and the next generation.
    Sawyer TK; Wu JC; Sawyer JR; English JM
    Expert Opin Investig Drugs; 2013 Jun; 22(6):675-8. PubMed ID: 23705633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
    Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecule of the month. Temsirolimus.
    Drug News Perspect; 2007; 20(6):406. PubMed ID: 17925894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.